- Home
- TAL vs RVMD Comparison
TAL vs RVMD Comparison
Compare TAL & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAL
- RVMD
- Stock Information
- Founded
- TAL 2003
- RVMD 2014
- Country
- TAL China
- RVMD United States
- Employees
- TAL N/A
- RVMD N/A
- Industry
- TAL Other Consumer Services
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TAL Real Estate
- RVMD Health Care
- Exchange
- TAL Nasdaq
- RVMD Nasdaq
- Market Cap
- TAL 8.1B
- RVMD 8.7B
- IPO Year
- TAL 2010
- RVMD 2020
- Fundamental
- Price
- TAL $12.90
- RVMD $39.20
- Analyst Decision
- TAL Strong Buy
- RVMD Strong Buy
- Analyst Count
- TAL 2
- RVMD 13
- Target Price
- TAL $15.30
- RVMD $67.77
- AVG Volume (30 Days)
- TAL 7.1M
- RVMD 1.4M
- Earning Date
- TAL 04-24-2025
- RVMD 05-07-2025
- Dividend Yield
- TAL N/A
- RVMD N/A
- EPS Growth
- TAL N/A
- RVMD N/A
- EPS
- TAL 0.19
- RVMD N/A
- Revenue
- TAL $2,069,557,000.00
- RVMD N/A
- Revenue This Year
- TAL $53.31
- RVMD N/A
- Revenue Next Year
- TAL $33.96
- RVMD $153.09
- P/E Ratio
- TAL $67.46
- RVMD N/A
- Revenue Growth
- TAL 55.62
- RVMD N/A
- 52 Week Low
- TAL $7.35
- RVMD $29.55
- 52 Week High
- TAL $15.30
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- TAL 46.82
- RVMD 48.06
- Support Level
- TAL $12.72
- RVMD $36.13
- Resistance Level
- TAL $13.47
- RVMD $40.87
- Average True Range (ATR)
- TAL 0.62
- RVMD 1.96
- MACD
- TAL -0.18
- RVMD 0.03
- Stochastic Oscillator
- TAL 25.57
- RVMD 61.36
About TAL TAL Education Group
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions, and the like. Among those business lines, TAL focuses on enrichment learning and content solutions.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.